within Pharmacolibrary.Drugs.N_NervousSystem.N07A_Parasympathomimetics.N07AX03_Cevimeline;

model Cevimeline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 0.0002586111111111111,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.009300000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.021666666666666667,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cevimeline</td></tr><tr><td>ATC code:</td><td>N07AX03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>13.3</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cevimeline is a cholinergic agonist that selectively stimulates muscarinic M1 and M3 receptors, enhancing exocrine gland secretion, particularly saliva. It is primarily approved for the treatment of symptoms of dry mouth (xerostomia) associated with Sjögren’s syndrome. Cevimeline is an orally administered medication and remains in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral 30 mg dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07AX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cevimeline;
